https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-11-11 / Cancer Immunol. Immunother. 2011 Jan;60(1):87-97
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-11-11 / Cancer Immunol. Immunother. 2011 Jan;60(1):87-972010-11-11 00:00:002019-02-15 08:50:09An autologous dendritic cell canine mammary tumor hybrid-cell fusion vaccine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-11-11 / Cancer Immunol. Immunother. 2011 Feb;60(2):249-60
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-11-11 / Cancer Immunol. Immunother. 2011 Feb;60(2):249-602010-11-11 00:00:002019-02-15 08:49:22Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-11-08 / Strahlenther Onkol 2010 Nov;186(11):587-99
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-11-08 / Strahlenther Onkol 2010 Nov;186(11):587-992010-11-08 00:00:002019-02-15 08:39:20Combination of ionising irradiation and hyperthermia activates programmed apoptotic and necrotic cell death pathways in human colorectal carcinoma cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-11-08 / Proc. Natl. Acad. Sci. U.S.A. 2010 Nov;107(47):20477-82
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-11-08 / Proc. Natl. Acad. Sci. U.S.A. 2010 Nov;107(47):20477-822010-11-08 00:00:002019-02-15 09:17:26NADPH oxidase-mediated reactive oxygen species production activates hypoxia-inducible factor-1 (HIF-1) via the ERK pathway after hyperthermia treatment
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-11-04 / Clin. Dev. Immunol. 2010;2010:517493
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-11-04 / Clin. Dev. Immunol. 2010;2010:5174932010-11-04 00:00:002019-02-15 08:52:55Dendritic cell-based immunotherapy for prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-11-04 / Head Neck 2011 Oct;33(10):1394-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-11-04 / Head Neck 2011 Oct;33(10):1394-92010-11-04 00:00:002019-02-15 09:21:37Therapeutic effects of a fusogenic newcastle disease virus in treating head and neck cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-11-01 / Expert Opin Biol Ther 2010 Nov;10(11):1539-53
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-11-01 / Expert Opin Biol Ther 2010 Nov;10(11):1539-532010-11-01 00:00:002019-02-15 08:40:15Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-11-01 / Tumori 2010 Nov-Dec;96(6):902-10
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-11-01 / Tumori 2010 Nov-Dec;96(6):902-102010-11-01 00:00:002019-02-15 09:17:22The role of hyperthermia in the battle against cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-11-01 / Gan To Kagaku Ryoho 2010 Nov;37(12):2243-5
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-11-01 / Gan To Kagaku Ryoho 2010 Nov;37(12):2243-52010-11-01 00:00:002019-02-15 09:17:23[Multidisciplinary therapy for 984 cancer patients–hyperthermic immunotherapy]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-11-01 / Neoplasia 2010 Nov;12(11):906-14
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-11-01 / Neoplasia 2010 Nov;12(11):906-142010-11-01 00:00:002019-02-15 08:52:56RIG-I helicase-independent pathway in sendai virus-activated dendritic cells is critical for preventing lung metastasis of AT6.3 prostate cancer
